VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 30, 2007) - Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) today announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes. Compounds in development are chosen on the basis of selectivity (the ability to home in on one receptor), potency and pharmacokinetics (drug distribution in the body over time). Compounds targeting these indications and exhibiting the desired characteristics are present in the FM-TP2000 and 3000 Series.
